BioWorld

Aug. 25, 2003

Pain Therapeutics Optimistic In Filing For Public Sale Of Shares

Looking to bolster cash reserves as it continues late-stage development of its lead products, Pain Therapeutics Inc. registered with the SEC for a follow-on stock offering that could raise about $51.6 million. (BioWorld Today) Read More

FDA Publishes Action Plan On Steps To Improve Efficiency

What's French Secret Of Red Wine Longevity? Genes, Proteins Yield New Molecules Protecting Elderly

Companies Line Up Against Columbia's New Patent Claims

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Neutrophils put the brakes on fat loss

BioWorld Science

Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Peptidream reveals milestone in Alnylam collaboration

BioWorld Science

Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...